LONDON – New guidelines for stem cell research open the door to extending the legal limit on human embryo research beyond the current 14-day maximum set down 40 years ago. In revised guidelines, the International Society for Stem Cell Research (ISSCR) has moved research on human embryos from category 3, which explicitly bans their study in culture post 14 days in any circumstances, to category 2B, in which research post 14 days would be permissible if there is a clear scientific rationale – and after a thorough specialized review.

Researchers at the Walter and Eliza Hall Institute for Medical Research in Melbourne, Australia, have used a newly developed single-cell clonal multiomics technique to gain a better understanding of the genetic programming underlying how stem cells differentiate into particular cell types.

Though Quralis Corp., of Cambridge, Mass., has been developing its pipeline for more than three years, the company now has a $42 million series A in hand to continue researching and developing therapies for amyotrophic lateral sclerosis and frontotemporal dementia.

PERTH, Australia – Mesoblast Ltd. plans to evaluate remestemcel-L in patients with acute respiratory distress syndrome caused by coronavirus (COVID-19) in the U.S., Australia, China and Europe.

PERTH, Australia – Australian stem cell therapy company Mesoblast Ltd. plans to evaluate its allogeneic mesenchymal stem cell (MSC) candidate, remestemcel-L, in patients with acute respiratory distress syndrome (ARDS) caused by coronavirus (COVID-19) in the U.S., Australia, China and Europe.